ProCE Banner Activity

CE / CME

Medical Minute 2: Cardiovascular Risk Reduction Strategies With GLP-1 Receptor Agonists

Multimedia

Learn from cardiology and endocrinology experts on the importance of integrating GLP-1 RAs into practice to improve cardiovascular risk reduction. Discuss current and emerging cardiovascular data for the use of GLP-1 RAs and learn from a case-based discussion among faculty.

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: November 13, 2023

Expiration: November 12, 2024

Share

Faculty

Darren K. McGuire

Darren K. McGuire, MD, MHSc, FACC

Distinguished Teaching Professor of Medicine
Jere H. Mitchell, MD Distinguished Chair in Cardiovascular Science
Division of Cardiology, Department of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Anne Peters

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

Payal Kohli

Payal Kohli, MD, FACC

Associate Adjunct Professor in Cardiology Division, Department of Medicine, Duke University
Associate Clinical Professor of Medicine, University of Colorado Anshutz
Founder and Medical Director, Cherry Creek Heart
On-Air Medical Expert, Tegna Broadcasting
Aurora, Colorado

Richard E. Pratley

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Novo Nordisk.

Novo Nordisk

Target Audience

This program is intended for cardiologists, primary care physicians, endocrinologists, nurse practitioners (NPs), physician assistants/physician associates (PAs), and other HCPs who manage patients with T2D with risk factors or established CV disease.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with type 2 diabetes (T2D) at high risk of cardiovascular events.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the latest CV outcomes data and guideline recommendations for GLP-1 RA therapies in the management of T2D

  • Incorporate GLP-1 RAs into the treatment of patients with T2D and CV risk based on dosing recommendations, the latest evidence, and patient needs

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Darren K. McGuire, MD, MHSc, FACC

Distinguished Teaching Professor of Medicine
Jere H. Mitchell, MD Distinguished Chair in Cardiovascular Science
Division of Cardiology, Department of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Darren K. McGuire, MD, MHSc, FACC: consultant/advisor/speaker: Afimmune, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck; researcher: Afimmune, AstraZeneca, Esperion, Lilly, Merck, Novo Nordisk, Sanofi.

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

Anne Peters, MD: consultant/advisor/speaker: Abbott Diabetes Care, Lilly, Vertex, Zealand; researcher: Abbott Diabetes Care, Insulet.

Primary Author

Payal Kohli, MD, FACC

Associate Adjunct Professor in Cardiology Division, Department of Medicine, Duke University
Associate Clinical Professor of Medicine, University of Colorado Anshutz
Founder and Medical Director, Cherry Creek Heart
On-Air Medical Expert, Tegna Broadcasting
Aurora, Colorado

Payal Kohli, MD, FACC: consultant/advisor/speaker: Agepha Pharma, Amarin, Amgen, AstraZeneca, Boston Scientific, Esperion, Merck, Zoll.

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida

Richard E. Pratley, MD: researcher (paid to institution): Dompe, Novo Nordisk; consultant/speaker (paid to institution): Bayer AG, Endogenex, Gasherbrum Bio, Hengrui, Intas Pharmaceuticals, Lilly, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceutical, Sun Pharmaceutical Industries.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Lucia M. Novak, MSN, ANP-BC, BC-ADM and Amy Butts, PA-C as noted below:

Lucia M. Novak, MSN, ANP-BC, BC-ADMconsultant/advisor/speaker: Abbott Diabetes Care, Ascencia, Boehringer Ingelheim, Boehringer Ingelheim-Lilly Alliance, Medtronic, Novo Nordisk.

Amy Butts, PA-C: consultant/advisor/speaker: Abbott, Bayer, Novo Nordisk, Sanofi.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2023, through November 12, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until November 12, 2024. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).